The first single-center, randomized controlled trial of TXA for acute spontaneous ICH conducted in Nepal.
Our findings suggest that intravenous TXA, administered within 24 hours of ICH onset, significantly reduces hematoma expansion without major complications. TXA, combined with blood pressure control, is beneficial in LMICs where immediate definitive neurosurgical care may be unavailable or during patient transfer.
This safe, affordable treatment reduces 180-day mortality and lowers the need for surgical intervention.
To read the article, click on https://doi.org/10.4103/neurol-india.Neurol-India-D-25-00950
